Acetylon Pharmaceuticals Presents Data on the Potent Activity of Ricolinostat (ACY-1215) in Preclinical Models of Lymphoma

16-12-2013 Business Wire HealthComments (0)


BOSTON--(BUSINESS WIRE)--Acetylon presented data on potent activity of ricolinostat (ACY-1215) in preclinical models of lymphoma, both as single agent and in combination with Velcade, Imbruvica and PI3K inhibitors.

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top